These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32270727)

  • 41. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
    Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
    Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M; Watanabe K; Fukuda T; Miura O
    Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.
    Olszewski AJ; Winer ES; Castillo JJ
    Leuk Res; 2014 Aug; 38(8):866-73. PubMed ID: 24837081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
    Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical Characteristics and Prognosis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma].
    Zheng WS; Guan LX; Cheng LC; Hu YL; Peng B; Bo J; Wang QS; Gao XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1551-1557. PubMed ID: 33067953
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
    Shaw J; Harvey C; Richards C; Kim C
    Leuk Lymphoma; 2019 Dec; 60(13):3235-3243. PubMed ID: 31185769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical characteristics of 46 pediatric diffuse large B-cell lymphoma and treatment outcome].
    Huang S; Yang J; Jin L; Duan YL; Zhang M; Zhang NN; Li Q; Zhang N; Zhou CJ; Zhang YH
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):774-779. PubMed ID: 31594064
    [No Abstract]   [Full Text] [Related]  

  • 50. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
    Elstrom RL; Martin P; Ostrow K; Barrientos J; Chadburn A; Furman R; Ruan J; Shore T; Schuster M; Cerchietti L; Melnick A; Coleman M; Leonard JP
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):192-6. PubMed ID: 20511164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
    Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
    Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center.
    Lee RC; Zou D; Demetrick DJ; Difrancesco LM; Fassbender K; Stewart D
    Value Health; 2008; 11(2):221-30. PubMed ID: 18380634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C; Hind D; Brewer N; Abbott V
    Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival of patients with transformed lymphoma in the rituximab era.
    Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
    Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
    Kadota T; Seo S; Fuse H; Ishii G; Itoh K; Yano T; Kaneko K; Tsukasaki K
    Cancer Med; 2019 Mar; 8(3):982-989. PubMed ID: 30730104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab.
    Smith SD; Bolwell BJ; Rybicki LA; Kang T; Dean R; Advani A; Thakkar S; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
    Bone Marrow Transplant; 2011 Feb; 46(2):262-6. PubMed ID: 20479706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy.
    Seshadri T; Stakiw J; Pintilie M; Keating A; Crump M; Kuruvilla J
    Hematology; 2008 Oct; 13(5):261-6. PubMed ID: 18854087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
    Howlader N; Mariotto AB; Besson C; Suneja G; Robien K; Younes N; Engels EA
    Cancer; 2017 Sep; 123(17):3326-3334. PubMed ID: 28464214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.